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Background: The associations of metabolic syndrome (MetS) or diabetes mellitus (DM) on long-term survival after
coronary artery bypass grafting (CABG) have not been extensively evaluated. The aim of the present study was to
assess the impact of MetS and DM on the 16-year survival after CABG.
Methods: Diabetic and metabolic status together with relevant cardiovascular data was established in 910 CABG
patients operated in 1993-94. They were divided in three groups as follows: neither DM nor MetS (375 patients),
MetS alone (279 patients) and DM with or without MetS (256 patients). The 16-year follow-up of patient survival
was carried out using national health databases. The relative survival rates were analyzed using the Life Table
method comparing the observed survival rates of three patient groups to the rates based on age-, sex- and
time-specific life tables for the whole population in Finland. To study the independent significance of MetS and DM
for clinical outcome, multivariate analysis was made using an optimizing stepwise procedure based on the Bayesian
approach.
Results: Bayesian multivariate analysis revealed together six variables to predict clinical outcome (2 months to 16
years) in relation to the national background population, i.e. age, diabetes, left ventricular ejection fraction, BMI,
perfusion time during the CABG and peripheral arterial disease. Our principal finding was that after postoperative
period the 16-year prognosis of patients with neither DM nor MetS was better than that of the age-, sex-and
time-matched background population (relative survival against background population 1.037, p < 0.0001). The
overall survival of MetS patients resembled that of the matched background population (relative survival 0.998, NS).
DM was associated with significantly increased mortality (relative survival 0.86, p < 0.0001). Additionally, mortality
was even higher in patients receiving insulin treatment than in those without. Excess death rate of DM patients was
predominantly caused by cardiovascular causes.
Conclusion: In this long-term follow-up study patient groups without diabetes had at least equal 16 years’ survival
after CABG than their matched background populations. Survival of DM patients started to deteriorate already few
years after the operation.
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Figure 1 Schematic description of study patients. CABG= coronary
artery bypass grafting, DM = diabetes mellitus, MetS =metabolic
syndrome, Non-insulin DM = diabetic patients without insulin
treatment. Insulin DM= diabetic patients treated with insulin.
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Metabolic syndrome (MetS), was first officially defined by
the World Health Organization (WHO) and the National
Cholesterol Education Program (NCEP) more than ten
years ago [1,2]. Since that time its epidemiology has
been widely evaluated [3,4]. MetS can be used as a tool
to characterize patients at added risk [5-7]. Several
studies have suggested that the risks of premature death
and cardiovascular disease or diabetes are higher among
subjects with MetS compared to those without. However,
follow-up studies on long-term survival after coronary
artery bypass grafting (CABG) have yielded controversial
results with regard to the impact of MetS [8,9].
Diabetes (DM) is a prominent cardiovascular risk factor
[10,11]. There is a considerable body of evidence on poor
early outcome and higher in-hospital morbidity in dia-
betics compared with non-diabetic patients after CABG
[12,13]. The association of diabetes on long-term survival
after CABG has not been extensively evaluated. The few
reports published comparing the type of treatment of
diabetes to the long-term prognosis after CABG have
come to conflicting conclusions [14,15].
Our aim was to evaluate the assumed detrimental impact
of metabolic syndrome and diabetes mellitus on long-term
prognosis after CABG, focusing on survival after the first
two postoperative months.Methods
Study population
The population of the Working after CABG (W-CABG)
study has been described elsewhere [16]. Briefly, CABG
was done on 961 patients in Tampere University Hospital
during a period of 18 months in 1993-94. Data on MetS
and DM were available on 945 operated patients and 910
patients survived two months after CABG (Figure 1).
These patients formed the study cohort and were followed
for 16 years.
We analyzed the survival of CABG patients in three
groups as follows: neither DM nor MetS (DM-/MetS-),
MetS alone (DM-/MetS+) and DM with or without MetS
(DM+). We combined all DM patients in the same group
regardless of their status concerning MetS, in primary
analyses of diabetic patients the presence of MetS did not
affect survival.Data collection and clinical definitions
The background of the patients and perioperative data
were collected from the medical records in Tampere
University Hospital and the secondary hospitals involved
in the postoperative care. A survival analysis was made
after the closing day, June 30, 2010, based on data ob-
tained from the Statistical Office of Finland. The results
of the full completed 16-year follow-up are given.Diagnoses of hypertension, peripheral vascular disease,
previous myocardial infarction, and previous transient
ischemic attack (TIA) or stroke were established from
patient records. Renal dysfunction was defined as a
glomerular filtration rate less than 60 ml/min/1,73 m2
calculated with the CKD-EPI equation [17]. Patients
were defined as hypercholesterolemic if they had total
cholesterol ≥5 mmol/l (200 mg/dl) (NCEP ATP III) or
were on lipid-lowering drug therapy. Smoking habits
were based on a questionnaire completed 21 months
postoperatively [16].
Classification of MetS was made according to the NCEP/
ATP III definition with the exception that body mass index
(BMI) (kg/m2) was used as a measure of obesity. During
the 1990s waist circumference was not commonly mea-
sured [9,18]. Modified MetS was defined as the presence of
three or more of the following risk factors: BMI > 30 kg/m2
for men and > 25 kg/m2 for women, TGL concentration ≥
150 mg/dL (1.7 mmol/l), HDL-C < 40 mg/dL (1.03 mmol/l)
for men and < 50 mg/dL (1.3 mmol/l) for women and
systolic blood pressure ≥ 130 mmHg or diastolic blood
pressure ≥ 85 mmHg or on antihypertensive medication.
Elevated blood glucose was defined as fasting blood glu-
cose ≥ 100 mg/dl (5.6 mmol/l) [1,2]. For the diagnosis of
diabetes the 1998 WHO criteria were used, defining fasting
blood glucose level (fB-gluk) ≥ 110 mg/dL (6.1 mmol/l) or
random blood glucose ≥ 180 mg/dL (10.0 mmol/l) [1]. A
patient was also defined as diabetic if on antidiabetic medi-
cation according either to hospital records or the reim-
bursement database maintained by the Social Insurance
Institution of Finland. Further they were divided in insulin-
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and in non-insulin-treated diabetics based on hospital re-
cords at the time of admission for CABG. BMI was calcu-
lated as mass/height2 (kg/m2).
Cardiovascular death was defined as any death caused
by coronary heart disease or sudden death during 2
months to 16 years postoperatively. Stroke was consid-
ered as cardiovascular death.Survival analysis
Overall survival (0-16 years postoperatively) was analyzed,
including hospital and immediate postoperative survival
for 945 patients. Separate survival analyses (2 months to
10 and 16 years) were then carried out for 910 patients,
focusing on survival after the immediate postoperative
phase. Survival analyses were made according to the meta-
bolic status of the patients (DM-/MetS-, DM-/MetS+ and
DM+). The cumulative relative mortality for each group
was calculated in 2-month steps against age-, sex- and
time-specific national background populations as de-
scribed in Statistical methods. The first subanalysis was
then made in similar manner to reveal survival of DM
patients with and without insulin therapy. In the second
subanalysis the association of MetS (yes or no) with sur-
vival was identically studied in DM patients. The study
protocol was approved by the Ethics Committee of
Tampere University Hospital.Statistical methods
In the comparison of patient characteristics, categorical
data are tabulated as frequencies and percentages, and
continuous variables are expressed as mean and SD. Dif-
ferences between two groups were tested by Chi squared
test and the Wilcoxon rank test, and in cases of more
than two groups by Kruskal-Wallis test. Fisher’s exact
test was used when appropriate in two-by-two tables with
directed hypothesis. Differences in mean values between
two groups were tested by Student’s t-test and in the case
of more than two groups by analysis of variance.
The relative survival rate was analyzed by sex, age,
DM and MetS using the Life Table method [19]. In this
approach, the observed survival rates of the groups are
compared to the rates based on age-, sex- and time-
specific life tables for the whole population in Finland.
Calculation of survival rates was based on the individual
life expectancies of the target population for the target
years (reference population). The survival of the reference
population is effectively 1.00. If the survival curve of the
group remains below that of the reference population
there is excess mortality in the group.
To study the independent significance of MetS and DM
for clinical outcome (2 months to 16 years), multivariate
analysis was made using an optimizing stepwise procedurebased on the Bayesian approach [20]. This procedure was
developed for nominal variables, and does not require a
perfect variable matrix. It selects, by the heuristic ap-
proach, the combination of variables which best explains
the selected outcome factor. The Bayesian approach is ap-
plied by counting posterior likelihood ratios or odds ratios
for each combination. The aim was to find an optimal
subset of pre-and intraoperative variables to provide the
best explanation. The parameters included in the multi-
variate analysis were age, gender, BMI, all significant
cardiometabolic diseases and related operations as well
as cardiac, lipid lowering and psychiatric medications.
Also essential intraoperative characteristics of CABG
were included in the analysis. Altogether 31 parameters




The essential clinical characteristics of the 910 patients
are shown in Table 1. Their mean age was 61.6 (SD 8.4)
years; 191 of them were women (mean age 64.8 [SD 7.5]
years) and 719 men (mean age 60.8 [SD 8.4] years). Of
the 910 subjects, 41% were free of MetS or DM and 31%
had MetS without DM (Figure 1).
Non-diabetic patients with MetS had by definition more
often metabolic abnormalities than those without MetS
(Table 1). Similar findings were obtained in patients with
diabetes, of whom 82% had MetS. Non-diabetic patients
without MetS had more often normal renal function than
others (P < 0.01). Diabetic patients were older having more
angina pectoris and peripheral arterial disease than other
patients (Table 1). Smoking habits and the prevalence of
hypercholesterolemia did not differ between the three
groups.
Overall survival
No patients were lost during the 16-year follow-up. The
overall postoperative survival is presented in Figure 2.
DM was associated with significantly unfavourable prog-
nosis compared to the non-diabetic patients in the two
other groups (both p < 0.001). The difference in survival
was already seen during the course of the first two post-
operative months, where a total of 35 out of 945 patients
(3.7%) died. Among non-diabetic patients there was no
difference between subjects with or without MetS.
Long-term survival against background population
The analysis between 2 months and 16 years revealed
that of the 910 patients alive two months postoperatively
432 (47.5%) had died. Figure 3A presents the relative sur-
vival of the three study groups matched by age, gender
and calendar year against their respective Finnish back-
ground populations (relative survival = 1.00). After the
Table 1 Preoperative demographic data, clinical characteristics and severity of coronary heart disease in 910 patients
surviving two months after CABG
DM–/MetS– DM–/MetS+ DM+ Overall
n = 375 n = 279 n = 256 p-value
Female (%) 15.2 26.2 23.8 <0.011,2
Mean Age (years) (SD) 61.3 (8.2) 60.7 (8.6) 63.3 (8.4) <0.0012,3
Variables of Modified MetS
BMI (kg/ m2) 25.8 28.7 28.1 NA
Elevated Blood Pressure (%) 40.9 83.1 67.5
HDL Cholesterol (low, %) 44.9 90.2 65.3
Triglyceride (high, %) 27.4 83.7 67.7
Elevated Glucose or DM (%) 4.5 25.8 100.0
Concomitant Diseases
Hypercholesterolemia (%) 69.5 80.3 77.7 NS
Previous MI (%) 70.5 67.8 67.7 NS
Previous TIA or stroke (%) 8.9 8.6 13.9 NS
Intermittent Claudication (%) 6.2 4.7 18.6 <0.0013,4
Renal Function
CreaCl (ml/min) (SD) 76.4 (13.8) 74.2 (18.2) 73.7 (16.9) NS
CreaCl < 60 ml/min/1,73 m2 (%) 11.0 19.0 19.7 <0.011,2
Preoperative Smoking (%) 66.6 60.2 66.4 NS
Severity of Heart Disease
EF (%) (SD) 60 (14) 61 (13) 58 (14) <0.055
EF ≤ 35% (%) 7 4 11 <0.055
NYHA II (%) 11.9 13.0 6.5
NYHA III (%) 59.9 54.3 56.3 <0.055
NYHA IV (%) 28.2 32.6 37.2
Operation Characteristics
Three–vessel Disease (%) 61.1 59.7 58.6 NS
Left Main Disease (%) 13.1 16.6 14.1 NS
Number of Grafts 3.39 3.38 3.35 NS
Use of Arterial Grafts (%) 86.3 83.4 81.0 NS
Concomitant Operation (%) 6.1 3.3 7.6 NS
Perfusion Time (SD) 107.0 (36.6) 108.0 (58.8) 112.3 (34.2) NS
Urgent or Emergency Operation (%) 26.7 29.9 33.5 NS
Abbreviations: MI myocardial infarct, TIA transient ischemic attack, EF ejection fraction, NYHA angina pectoris symptoms according to New York Heart Association,
CHD coronary heart disease, LM left main, low HDL cholesterol: men < 1.03 mmol/l, women < 1.3 mmol/l, elevated triglycerides: ≥ 1.7 mmol/l,
NS = not significant, NA = not applicable.
1Unadjusted p < 0.01 by the pooled t-test for the comparison DM-/MetS+ against DM-/MetS-.
2Unadjusted p < 0.01 by the pooled t-test for the comparison DM+ against DM-/MetS-.
3Unadjusted p < 0.001 by the pooled t-test for the comparison DM+ against DM-/MetS+ .
4Unadjusted p < 0.001 by the pooled t-test for the comparison DM+ against DM-/MetS-.
5Unadjusted p < 0.05 by the pooled t-test for the comparison DM+ against other groups.
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DM-/MetS- patients was 1.037, (95% CI, 1.026 to 1.048;
< 0.0001) compared to that of the background popula-
tion. For the first 10 postoperative years the relative sur-
vival was 1.033 (95% CI, 1.021 to 1.045; p < 0.0001).Metabolic syndrome and long-term survival
In non-diabetic patients with MetS the long-term survival
between 2 months and 16 years was poorer than among
patients without MetS (P < 0.0001). However, during the
same period the relative survival of DM-/MetS+ patients
Figure 2 Postoperative absolute survival of patients with
neither diabetes nor metabolic syndrome (DM-/MetS-), patients
with only metabolic syndrome (DM-/MetS+) and patients with
diabetes regardless of metabolic syndrome (DM+) during the
16-year follow-up. Comparison between DM-/MetS- and DM-/MetS+:
NS Comparison of DM+ against both groups: P < 0.001. Follow-up
of the first two months is shown in the small inset (n = 945).
Figure 3 The actual survival 2 months–16 years postoperatively comp
(relative survival 1.00, n = 910). A. DM-/MetS- = patients with neither diab
syndrome. DM+ = diabetic patients. B. No DM = patients without diabetes
DM = diabetic patients treated with insulin.
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(relative survival, 0.998; 95% CI, 0.978 to 1.018; NS).
During the first 10 postoperative years, the relative
survival of DM-/MetS+ patients was 1.8% better than that
of the matched background population (relative survival,
1.018; 95% CI, 1.010 to 1.026; p < 0.0001) but subsequently
deteriorated thereafter (Figure 3A).
Diabetes mellitus and long-term survival
In the postoperative period of 2 months to 16 years, the
survival of patients with DM was significantly inferior
compared to the background population (relative survival,
0.86; 95% CI, 0.82 to 0.90) and to both non-diabetic pa-
tient groups (all p < 0.0001; Figure 3A). DM patients on
insulin therapy had poorer survival than those with not on
insulin (p < 0.01, Figure 3B).
Among patients with DM, MetS seemed not to affect
postoperative survival (2 months-16 years) after adjust-
ment for age, gender and time (absolute survivals, 0.39;ared to that of the age-and sex-matched Finnish population
etes nor metabolic syndrome. DM-/MetS+ = patients with only metabolic
. Non-insulin DM = diabetic patients without insulin treatment. Insulin
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0.10 to 0.62 for DM+/MetS-, NS).
Causes of death
Cardiovascular and non-cardiovascular death rates were
17.1% and 20.5% for DM-/MetS-, 18.3% and 21.5% for
DM-/MetS+ and 38.7% and 28.1% for DM+ patients, re-
spectively. Further, out of all deaths the corresponding
proportions of cardiovascular deaths were 45.4%, 45.9%
and 56.1%, respectively (p < 0.0001 between DM-and
DM+ patients). Stroke was reported as a cause of death
in only five patients.
Best predictors of long-term prognosis
Bayesian multivariate analysis revealed together six vari-
ables to predict clinical outcome (2 months to 16 years)
in relation to the national background population, i.e. age,
diabetes, left ventricular ejection fraction, BMI, perfusion
time during the CABG and peripheral arterial disease.
Using this model, the measure of agreement (kappa =
0.45) was moderate.
Discussion
To the best of our knowledge this study is the first in
which the survival of non-diabetic and diabetic CABG
patients was compared to that of matched background
populations.
Our principal finding was that the long-term prognosis
of patients with neither diabetes nor metabolic syndrome
was better than that of the age-, sex-and time-matched
background population. Further, in non-diabetic patients
the presence of metabolic syndrome reduced long-term
survival after CABG when compared to those without
MetS. However, the mortality of MetS patients was not
significantly inferior to that of the matched background
population, which might reflect the careful postoperative
follow-up and treatment of known risk factors of operated
MetS patients.
Not surprisingly, DM was associated with significantly
increased intermediate-and long-term mortality. Survival
was even shorter if the diabetes treatment strategy in-
cluded insulin compared to patients without insulin
therapy. MetS per se did not impair survival among
diabetic patients.
MetS, glucose intolerance and insulin resistance form
together complex relationships, whose interacting patho-
physiological roles are not yet fully understood. Insulin
resistance leads to glucose intolerance, if pancreatic
compensation processes are incomplete [21]. Glucose
abnormalities with or without diabetes predict cardio-
vascular events and mortality [22,23]. Insulin resist-
ance is also associated with MetS and its components
[24]. Further, MetS has been shown to worsen the
prognosis of coronary heart disease patients [25].However, until recently no studies have specifically ex-
amined the prognostic significance of MetS for longer
than 10 years after CABG.
Two studies have yielded different results regarding
the impact of metabolic syndrome [8,9]. In the BARI
trial no significant difference was seen in the death-rate
or MI during the 10-year follow-up between patients
with and without MetS [9]. In another study of CABG
patients MetS predicted inferior outcome in the group
of non-diabetic patients [8]. An increase in both all-
cause and cardiac mortality became apparent approxi-
mately 10 years after surgery. The detrimental effect of
MetS on survival was more marked in non-DM patients
than in DM patients [8]. Our data are in concordance
with and expand these findings.
Diabetes is associated with impaired outcome after
CABG [26-28]. However, relation of insulin treatment
on the long-term prognosis after CABG has been con-
troversial [14,15,29]. Thourani and Alserius with their
co-workers found independently that diabetic patients
had a poorer 10-year prognosis than non-diabetic pa-
tients [14,29]. In both studies insulin-treated patients
with diabetes had the poorest 10-year survival rate. Also,
in a 10-year follow-up of CABG patients Mohammadi
and colleagues found insulin-treated DM to be an inde-
pendent risk factor for long-term cardiac mortality [15].
However, in DM patients not on insulin therapy, the
cardiac-specific survival was similar to that observed in
non-diabetic patients [15].
Our results are in accord with the findings of Thour-
ani and Alserius, suggesting inferior survival of DM pa-
tients on insulin compared to those without insulin or
to non-diabetics. Insulin treatment might suggest more
severe and advanced diabetes in this cohort.
We found, that the excessive death rate of diabetics
was mostly but not completely related to cardiovascular
causes. Our results conform to the idea that long-lasting
DM is associated with a generalized vascular disease
which is characterized by impaired vascular endothelial
function and hypercogulation [14,29].
The strength of the present study is the reliability and
scope of the national registers used, allowing 100% cover-
age of the mortality data of our patients [30]. Our follow-
up includes all subjects operated, like those migrated in
the country and one patient moved in the neighbouring
country. The length of the postoperative follow-up was
exactly 16 years allowing conclusions more valid than
those based on a shorter follow-up. According to Finnish
health care policy every citizen has access to health care
mainly financed by taxes. So in the background population
such social factors, like a proportion of non-secured
citizens, did not affect our results [31].
Certain limitations should also be considered. Firstly,
the perioperative data were collected retrospectively [16].
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questionnaires and direct contacts, 16 (1.7%) out of the
original sample of 961 patients were excluded by reason
of insufficient data. Secondly, we identified BMI-based
obesity, not waist circumference, as a factor of the
metabolic syndrome. Nevertheless, BMI is widely used
in the modified definition of MetS and studies have
demonstrated concordance between the definitions of
MetS [7,18].
Conclusions
In this long-term follow-up study patients with neither
DM nor MetS had extremely good prognosis for at
least 16 years when compared to the matched back-
ground population. Also the survival of patients with
MetS but without DM had a good prognosis. Survival
of DM patients started to deteriorate already short
after the operation.
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